These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15452762)

  • 21. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
    Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
    Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Common methodological flaws in economic evaluations.
    Drummond M; Sculpher M
    Med Care; 2005 Jul; 43(7 Suppl):5-14. PubMed ID: 16056003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.
    Panteli D; Eckhardt H; Nolting A; Busse R; Kulig M
    Health Res Policy Syst; 2015 Sep; 13():39. PubMed ID: 26407728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Creating an efficient market for nursing home care.
    Hogan AJ
    Socioecon Plann Sci; 1982; 16(2):53-62. PubMed ID: 10255768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of pharmaceuticals: a European perspective.
    Drummond M; Rutten F; Brenna A; Pinto CG; Horisberger B; Jönsson B; Le Pen C; Rovira J; von der Schulenburg MG; Sintonen H
    Pharmacoeconomics; 1993 Sep; 4(3):173-86. PubMed ID: 10146921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget?
    Mauskopf J; Chirila C; Birt J; Boye KS; Bowman L
    Health Policy; 2013 Apr; 110(1):49-59. PubMed ID: 23434292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Why has the use of health economic evaluation in Japan lagged behind that in other developed countries?
    Ikegami N; Drummond M; Fukuhara S; Nishimura S; Torrance GW; Schubert F
    Pharmacoeconomics; 2002; 20 Suppl 2():1-7. PubMed ID: 12238943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Use of Economic Evidence to Inform Drug Pricing Decisions in Jordan.
    Hammad EA
    Value Health; 2016; 19(2):233-8. PubMed ID: 27021758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea.
    Bae G; Bae EY; Bae S
    Health Policy; 2015 May; 119(5):577-87. PubMed ID: 25666339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
    Andronis L; Barton P; Bryan S
    Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Physicians' experience with increased use of individual reimbursement for pharmaceuticals].
    Levorsen A; Kristiansen IS; Aasland OG
    Tidsskr Nor Laegeforen; 2008 Aug; 128(16):1829-32. PubMed ID: 18787593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time.
    Sandmann FG; Franken MG; Steenhoek A; Koopmanschap MA
    Health Policy; 2013 Oct; 112(3):285-96. PubMed ID: 23628483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Criteria for Drug Reimbursement Decision-Making: An Emerging Public Health Challenge in Bulgaria.
    Iskrov G; Stefanov R
    Balkan Med J; 2016 Jan; 33(1):27-35. PubMed ID: 26966615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea.
    Kwon SH; Park SK; Byun JH; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):411-419. PubMed ID: 28019130
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.